To fund the pre-clinical testing of a VERY EXCITING new breast cancer drug (TEQ103) in combination with an immunotherapy:
A POTENTIAL CURE
$100k is an ambitious goal BUT here is how it can be done:
It only requires 100 people each raising $1000.
And $1000 can be reached by asking 10 people to each donate or fundraise from others: $100.
And $100 is totally feasible when 10 people each donate $10.
The Powers Of 10..
..and remembering our why:
the 1 in 8 are us, our mothers, daughters, wives, aunts, sisters, nieces, cousins, friends...
our loved ones.
Metastatic Breast Cancer (MBC) is when breast cancer cells have spread to distant parts of the body to form new tumors.
It is incurable and deadly 99% of the time, but it receives the least amount of breast cancer research funding.
Help us fund research of the therapy combination TEQ103 & NK92 as it holds the potential for a real cure for some people living with MBC.
(Every penny raised will go towards this research and testing will be done solely on MBC models, using tumor organoids developed from people who died of the disease.)
Join Us For Two Virtual Q&A's With The Researchers Who Developed TEQ103:
Dr. David Shapiro & Dr. Paul Hergenrother
of the University of Illinois
The excitement about TEQ103 has been brewing in Metastatic Breast Cancer communities for some time and NOW is your chance to learn more about it and speak directly with the researchers who developed it.
A POTENTIAL CURE FOR
METASTATIC BREAST CANCER
TEQ103 & NK-92
North Star Cancer Research Foundation is launching a fundraising campaign to raise $100,000 in October 2025 to fund critical research by Dr. David Shapiro and Dr. Paul Hergenrother at University of Illinois.
This research focuses on the drug TEQ103 in combination with NK-92, a type of immune system cell that can be given as a cancer immunotherapy in clinical trials, representing a potential breakthrough treatment for metastatic breast cancer (MBC).
Metastatic Breast Cancer has proven very difficult to treat because cancer cells continue to adapt and become resistant to targeted treatments and chemotherapies. TEQ103 uniquely stimulates a response by Natural Killer cells and this combination therapy may prevent resistant cancer cells from escaping destruction.
With federal cancer research funding being slashed, outside support is urgently needed to keep advancing this work.
For more information on how this research will be conducted and to follow our fundraising progress, click on DONATE.